These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12625833)

  • 1. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women.
    Teerlink T; Neele SJ; de Jong S; Netelenbos JC; Stehouwer CD
    Clin Sci (Lond); 2003 Jul; 105(1):67-71. PubMed ID: 12625833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study.
    Verhoeven MO; Hemelaar M; van der Mooren MJ; Kenemans P; Teerlink T
    J Intern Med; 2006 Feb; 259(2):199-208. PubMed ID: 16420549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Verhoeven MO; Teerlink T; Kenemans P; Vogelvang TE; van der Mooren MJ;
    Menopause; 2007; 14(2):235-42. PubMed ID: 17146377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
    Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
    Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.
    Mijatovic V; Netelenbos C; van der Mooren MJ; de Valk-de Roo GW; Jakobs C; Kenemans P
    Fertil Steril; 1998 Dec; 70(6):1085-9. PubMed ID: 9848300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women.
    Giltay EJ; Duschek EJ; Katan MB; Zock PL; Neele SJ; Netelenbos JC
    J Endocrinol; 2004 Sep; 182(3):399-408. PubMed ID: 15350182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.
    Post MS; Verhoeven MO; van der Mooren MJ; Kenemans P; Stehouwer CD; Teerlink T
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4221-6. PubMed ID: 12970290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
    Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study.
    Verhoeven MO; Hemelaar M; Teerlink T; Kenemans P; van der Mooren MJ
    Atherosclerosis; 2007 Nov; 195(1):181-8. PubMed ID: 17084844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.
    Vogelvang TE; Mijatovic V; Kamp O; Netelenbos JC; Neele SJ; Pines A; Kenemans P; van der Mooren MJ
    Am J Obstet Gynecol; 2002 Apr; 186(4):729-36. PubMed ID: 11967499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone therapy and asymmetrical dimethylarginine in postmenopausal women.
    Karkanaki A; Vavilis D; Traianos A; Kalogiannidis I; Panidis D
    Hormones (Athens); 2010; 9(2):127-35. PubMed ID: 20687396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.
    Duschek EJ; de Valk-de Roo GW; Gooren LJ; Netelenbos C
    Fertil Steril; 2004 Aug; 82(2):384-90. PubMed ID: 15302288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women.
    Duschek EJ; Stehouwer CD; de Valk-de Roo GW; Schalkwijk CG; Lambert J; Netelenbos C
    J Intern Med; 2003 Jul; 254(1):85-94. PubMed ID: 12823645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans.
    Mittermayer F; Namiranian K; Pleiner J; Schaller G; Wolzt M
    Clin Sci (Lond); 2004 Jun; 106(6):577-81. PubMed ID: 14741043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
    Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo.
    Freedman M; San Martin J; O'Gorman J; Eckert S; Lippman ME; Lo SC; Walls EL; Zeng J
    J Natl Cancer Inst; 2001 Jan; 93(1):51-6. PubMed ID: 11136842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
    Vogelvang TE; Leurs JR; van der Mooren MJ; Mijatovic V; Hendriks DF; Neele SJ; Netelenbos JC; Kenemans P
    Menopause; 2004; 11(1):110-5. PubMed ID: 14716191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
    Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S;
    JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.